|
000
| 01473cam 2200289za 4500 |
|---|
| 001 | 9.848041 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107153600 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 171129s2018 onca o f000 0 eng d |
|---|
| 020 | |a9780660240534|z9780660240541 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-185/2017E-PDF |
|---|
| 110 | 2 |aNational Research Council Canada. |
|---|
| 245 | 10|aAnalytics for biologics and vaccines |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c2018. |
|---|
| 300 | |a[2] p. : |bcol. ill. |
|---|
| 500 | |aIssued also in French under title: Analytique pour produits biologiques et vaccins. |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"January 2018." |
|---|
| 520 | |a“Biologics and vaccine developers leverage our analytics expertise to advance their innovative treatments from discovery to application for clinical trials. We also transfer our data and methods to Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs), enabling them to offer new services while strengthening the Canadian biopharma ecosystem”--P. [1]. |
|---|
| 530 | |aIssued also in print format. |
|---|
| 693 | 4|aPharmaceutical biotechnology |
|---|
| 775 | 08|tAnalytique pour produits biologiques et vaccins |w(CaOODSP)9.848044 |
|---|
| 776 | 0#|tAnalytics for biologics and vaccines |w(CaOODSP)9.848042 |
|---|
| 856 | 40|qPDF|s143 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-185-2017-eng.pdf |
|---|